Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct

Washington DC’s district court handed Novartis a clear win late Friday, arguing that the Big Pharma can place conditions on the sales of drugs discounted by a federal program to contract pharmacies. But this interpretation was contradicted by another decision handed down Friday in a New Jersey district court, in which Novo Nordisk and Sanofi were told that they cannot unilaterally impose restrictions on the 340B program and that their new policies “must cease.”